DOCSLIB.ORG

TCF-001 TRACK (Target Rare Cancer Knowledge)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TCF-001 TRACK (Target Rare Cancer Knowledge) TCF-001 TRACK (Target Rare Cancer Knowledge) Cancers not listed here may be enrolled with the approval of the Principal Investigator on a case by case basis. Tier Tumor 1 EPITHELIAL TUMORS OF CERVIX UTERI 2 Squamous cell carcinoma with variants of cervix uteri 3 Squamous carcinoma 3 Squamous cell carcinoma nonkeratinizing, NOS 3 Squamous cell carcinoma keratinizing, NOS 3 Papillary squamous cell carcinoma 3 Papillary carcinoma, NOS 3 Verrucous/Warty carcinoma 3 Basaloid carcinoma 3 Squamous cell carcinoma spindle cell 3 Lymphoepithelial carcinoma 3 Transitional cell carcinoma, NOS 3 Glassy cell carcinoma 2 Adenocarcinoma with variants of cervix uteri 3 Adenocarcinoma, NOS 3 Adenocarcinoma with squamous metaplasia 3 Mucinous adenocarcinoma 3 Clear cell adenocarcinoma, NOS 3 Endometrioid adenocarcinoma, NOS 3 Serous cystadenocarcinoma, NOS 3 Signet ring cell carcinoma 3 Mesonephroma malignant 3 Villous adenocarcinoma 3 Mucinous adenocarcinoma, endocervical type 3 Adenocarcinoma intestinal type 3 Mixed cell adenocarcinoma 2 UnDifferentiateD carcinoma of cervix uteri 1 MIXED EPITHELIAL AND MESENCHYMAL TUMORS OF UTERUS 3 Mullerian mixed tumor 3 Adenosarcoma 1 EPITHELIAL TUMORS OF NASAL CAVITY AND SINUSES 2 Squamous cell carcinoma with variants of nasal cavity and sinuses 3 Squamous carcinoma 3 Verrucous carcinoma 3 Squamous cell carcinoma spindle cell 3 Papillary squamous cell carcinoma 3 Adenosquamous carcinoma Tier Tumor 3 Squamous cell carcinoma, adenoid 3 Basaloid squamous cell carcinoma 2 Lymphoepithelial carcinoma of nasal cavity and sinuses 2 UnDifferentiateD carcinoma of nasal cavity anD sinuses 2 Intestinal type adenocarcinoma of nasal cavity anD sinuses 1 EPITHELIAL TUMORS OF ESOPHAGUS 2 Squamous cell carcinoma with variants of esophagus 3 Squamous carcinoma 3 Adenosquamous carcinoma 3 Squamous cell carcinoma spindle cell 3 Verrucous carcinoma 3 Papillary squamous cell carcinoma 3 Basaloid squamous cell carcinoma 3 Squamous cell carcinoma, adenoid 2 Adenocarcinoma with variants of esophagus 1 EPITHELIAL TUMORS OF NASOPHARYNX 2 Squamous cell carcinoma with variants of nasopharynx 3 Squamous carcinoma 3 Squamous cell carcinoma nonkeratinizing, NOS 3 Squamous cell carcinoma keratinizing, NOS 3 Papillary squamous cell carcinoma 3 Basaloid squamous cell carcinoma 3 Squamous cell carcinoma, adenoid 3 Lymphoepithelial carcinoma 3 Undifferentiated carcinoma 2 Papillary adenocarcinoma of nasopharynx 1 EPITHELIAL TUMORS OF MAJOR SALIVARY GLANDS AND SALIVARY-GLAND TYPE TUMORS 2 Epithelial tumors of major salivary glanDs 3 Squamous carcinoma 3 Large cell carcinoma 3 Lymphoepithelial carcinoma 3 Carcinosarcoma, NOS 3 Adenocarcinoma NOS 3 Clear cell adenocarcinoma, NOS 3 Mucinous adenocarcinoma 3 Ductal carcinoma 3 Oxyphilic adenocarcinoma 3 Papillary cystadenocarcinoma, NOS 3 Adenoid cystic carcinoma 3 Mucoepidermoid carcinoma 3 Acinar cell adenocarcinoma 3 Malignant myoepithelioma Tier Tumor 3 Carcinoma in pleomorphic adenoma 3 Mixed tumor, malignant 3 Polymorphous low-grade adenocarcinoma 3 Basal cell adenocarcinoma 3 Epithelial-myoepithelial carcinoma 3 Sebaceous adenocarcinoma 3 Cystadenocarcinoma, NOS 3 Low grade cribriform cystadenocarcinoma 2 Salivary gland type tumors of head anD neck 3 Mucoepidermoid carcinoma 3 Adenocarcinoma NOS 3 Adenoid cystic carcinoma 3 Acinar cell adenocarcinoma 3 Ductal carcinoma 3 Mucinous adenocarcinoma 3 Basal cell adenocarcinoma 3 Clear cell adenocarcinoma, NOS 3 Epithelial-myoepithelial carcinoma 3 Polymorphous low grade adenocarcinoma 3 Carcinoma in pleomorphic adenoma 3 Malignant myoepithelioma 3 Cystadenocarcinoma, NOS 3 Oncocytic carcinoma 3 Papillary cystadenocarcinoma, NOS 2 Salivary gland type tumors of esophagus 3 Mucoepidermoid carcinoma 3 Adenoid cystic carcinoma 2 Salivary gland-type tumors of stomach 3 Mucoepidermoid carcinoma 3 Adenoid cystic carcinoma 2 Salivary gland type tumors of breast 3 Mucoepidermoid carcinoma 3 Adenoid cystic carcinoma 3 Myoepithelial carcinoma 3 Acinar cell adenocarcinoma 2 Salivary gland type tumors of bladDer 3 Adenoid cystic carcinoma 3 Mucoepidermoid carcinoma 2 Salivary gland type tumors of lung 1 EPITHELIAL TUMORS OF SMALL INTESTINE 2 Adenocarcinoma with variants of small intestine 3 Adenocarcinoma NOS 3 Mucinous adenocarcinoma Tier Tumor 3 Signet ring cell carcinoma 3 Adeno-squamous carcinoma 3 Medullary carcinoma, NOS 3 Undifferentiated carcinoma 2 Squamous cell carcinoma with variants of small intestine 3 Squamous carcinoma 2 Fibromyxoma anD low grade mucinous adenocarcinoma (pseuDomyxoma peritonei) of the appenDix 2 Acinar cell carcinoma of pancreas 2 Mucinous cystaDenocarcinoma of pancreas 2 IntraDuctal papillary mucinous carcinoma invasive of pancreas 2 Solid pseudopapillary carcinoma of pancreas 2 Serous cystadenocarcinoma of pancreas 1 EPITHELIAL TUMORS OF ANAL CANAL 2 Squamous cell carcinoma with variants of anal canal 3 Verrucous carcinoma 3 Undifferentiated carcinoma 3 Basaloid carcinoma of anal canal 2 Adenocarcinoma with variants of anal canal 3 Mucinous adenocarcinoma 2 Paget's disease of anal canal 1 EPITHELIAL TUMORS OF LIVER AND INTRAEPATIC BILE TRACT (IBT) 2 Hepatocellular carcinoma of Liver anD IBT 3 Combined hepatocellular carcinoma and cholangiocarcinoma 2 Hepatocellular carcinoma, fibrolamellar 2 Cholangiocarcinoma of IBT 2 Adenocarcinoma with variants of liver anD IBT 2 UnDifferentiateD carcinoma of liver anD IBT 2 Squamous cell carcinoma with variants of liver anD IBT 2 Bile Duct cystaDenocarcinoma of IBT 1 EPITHELIAL TUMORS OF GALLBLADDER AND EXTRAHEPATIC BILIARY TRACT (EBT) 2 Adenocarcinoma with variants of gallblaDDer 3 Cholangiocarcinoma 3 Papillary adenocarcinoma, NOS 3 Adenocarcinoma intestinal type 3 Mucinous adenocarcinoma 3 Clear cell adenocarcinoma, NOS 3 Signet ring cell carcinoma 3 Adeno-squamous carcinoma 3 Undifferentiated carcinoma 3 Bile duct cystadenocarcinoma 2 Adenocarcinoma with variants of EBT 3 Cholangiocarcinoma Tier Tumor 3 Papillary adenocarcinoma, NOS 3 Adenocarcinoma intestinal type 3 Mucinous adenocarcinoma 3 Clear cell adenocarcinoma, NOS 3 Signet ring cell carcinoma 3 Adeno-squamous carcinoma 3 Undifferentiated carcinoma 3 Bile duct cystadenocarcinoma 2 Squamous cell carcinoma of gallbladder and EBT 1 EPITHELIAL TUMOR OF TRACHEA 2 Squamous cell carcinoma with variants of trachea 3 Squamous carcinoma 3 Papillary squamous cell carcinoma 3 Basaloid squamous cell carcinoma 3 Squamous cell carcinoma clear cell type 3 Verrucous carcinoma 3 Squamous cell carcinoma, adenoid 3 Spindle cell carcinoma 3 Adeno-squamous carcinoma 3 Lymphoepithelial carcinoma 3 Giant cell carcinoma 3 Undifferentiated carcinoma 2 Adenocarcinoma with variants of trachea 3 Adenocarcinoma NOS 3 Mucinous adenocarcinoma 3 Papillary adenocarcinoma, NOS 3 Solid carcinoma, NOS 3 Clear cell adenocarcinoma, NOS 3 Acinar cell adenocarcinoma 3 Signet ring cell carcinoma 3 Mucinous cystadenocarcinoma, NOS 2 Salivary gland type tumors of trachea 3 Adenoid cystic carcinoma 3 Mucoepidermoid carcinoma 3 Myoepithelial carcinoma 2 Large cell carcinoma of lung 2 Salivary gland type tumors of lung 3 Adenoid cystic carcinoma 3 Mucoepidermoid carcinoma 3 Myoepithelial carcinoma 1 EPITHELIAL TUMORS OF THYMUS 2 Malignant thymoma Tier Tumor 3 Thymoma, malignant, NOS 3 Malignant thymoma, type AB 3 Malignant thymoma, type A 3 Malignant thymoma, type B 3 Malignant thymoma, type C 2 Squamous cell carcinoma of thymus 2 UnDifferentiateD carcinoma of thymus 2 Lymphoepithelial carcinoma of thymus 2 Adenocarcinoma with variants of thymus 3 Adenocarcinoma NOS 3 Papillary adenocarcinoma, NOS 2 Epithelial tumor of male breast 1 NON-EPITHELIAL TUMORS OF OVARY 2 Sex cord tumors of ovary 3 Granulosa cell tumor malignant 3 Granulosa cell tumor malignant, adult type 3 Granulosa cell tumor malignant, juvenile type 3 Sertoli-Leydig cell tumor poorly differentiated 3 Steroid cell tumor, malignant 2 Malignant/Immature teratomas of ovary 3 Teratoma, malignant, NOS 3 Struma ovarii, malignant 3 Primitive neuroectodermal tumor, NOS 3 Ependymoma 3 Medulloepithelioma, NOS 3 Glioblastoma 2 Germ cell tumor of ovary 3 Dysgerminoma/Seminoma 3 Yolk sac tumor 3 Mixed germ cell tumor 3 Embryonal adenocarcinoma 3 Choriocarcinoma, NOS 3 Polyembryoma 1 EPITHELIAL TUMORS OF VULVA AND VAGINA 2 Squamous cell carcinoma with variants of vulva and vagina 2 Adenocarcinoma with variants of vulva anD vagina 2 Paget's disease of vulva and vagina 2 UnDifferentiateD carcinoma of vulva anD vagina 1 TROPHOBLASTIC TUMOR OF PLACENTA 2 Choriocarcinoma of placenta 1 TESTICULAR AND PARATESTICULAR CANCERS 2 Paratesticular adenocarcinoma with variants Tier Tumor 3 Endometrioid adenocarcinoma, NOS 3 Clear cell adenocarcinoma, NOS 3 Serous cystadenocarcinoma, NOS 3 Mucinous cystadenocarcinoma, NOS 3 Collecting duct and rete testis carcinoma 3 Transitional cell carcinoma, NOS 2 Non-seminomatous testicular cancer 3 Mixed germ cell tumor 3 Teratocarcinoma 3 Choriocarcinoma combined with other germ cell elements 3 Embryonal adenocarcinoma, NOS 3 Yolk sac tumor 3 Choriocarcinoma, NOS 2 Seminomatous testicular cancer 3 Seminoma, NOS 2 Spermatocytic seminoma 2 Teratoma with malignant transformation 2 Testicular sex cord cancer 3 Leydig cell tumor malignant 3 Sertoli cell carcinoma 3 Malignant sex cord/gonadal stromal tumors 1 EPITHELIAL TUMORS OF PENIS 2 Squamous cell carcinoma with variants of penis 3 Squamous carcinoma 3 Adeno-squamous carcinoma 3 Verrocous carcinoma 3 Squamous cell carcinoma, sarcomatoid 3 Basaloid carcinoma 2 Adenocarcinoma with variants of penis 3 Extramammary Paget's disease 3 Sebaceous adenocarcinoma
Load more

Recommended publications
  • The Health-Related Quality of Life of Sarcoma Patients and Survivors In
    Cancers 2020, 12 S1 of S7 Supplementary Materials The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of A Nationwide Observational Study (PROSa) Martin Eichler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Susanne Singer, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Vitali Heidt, Christine Hofbauer, Marius Fried, Verena I. Gaidzik, Karl Verpoort, Marit Ahrens, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K. Schuler and the PROSa study group Includes Entities We included sarcomas according to the following WHO classification. - Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. 468 p. (World Health Organization classification of tumours). - Kurman RJ, International Agency for Research on Cancer, World Health Organization, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. 307 p. (World Health Organization classification of tumours). - Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19. - World Health Organization, Swerdlow SH, International Agency for Research on Cancer, editors. WHO classification of tumours of haematopoietic and lymphoid tissues: [... reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25 - 27, 2007]. 4. ed.
    [Show full text]
  • Rare Pancreatic Tumors
    Published online: 2020-04-29 THIEME 64 ReviewRare Pancreatic Article Tumors Choudhari et al. Rare Pancreatic Tumors Amitkumar Choudhari1,2 Pooja Kembhavi1,2 Mukta Ramadwar3,4 Aparna Katdare1,2 Vasundhara Smriti1,2 Akshay D. Baheti1,2 1Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Address for correspondence Akshay D. Baheti, MD, Department of Maharashtra, India Radiodiagnosis, Tata Memorial Hospital, Ernest , Borges Marg Parel 2Department of Radiodiagnosis, Homi Bhabha National University, Mumbai 400012, India (e-mail: [email protected]). Mumbai, Maharashtra, India 3Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India 4Department of Pathology, Homi Bhabha National University, Mumbai, Maharashtra, India J Gastrointestinal Abdominal Radiol ISGAR 2020;3:64–74 Abstract Pancreatic ductal adenocarcinoma, neuroendocrine tumor, and cystic pancreatic neo- plasms are the common pancreatic tumors most radiologists are familiar with. In this Keywords article we review the clinical presentation, pathophysiology, and radiology of rare pan- ► pancreatic cancer creatic neoplasms. While the imaging features are usually nonspecific and diagnosis is ► uncommon based on pathology, the radiology along with patient demographics, history, and lab- ► pancreatoblastoma oratory parameters can often help indicate the diagnosis of an uncommon pancreatic ► acinar cell neoplasm and guide appropriate management in these cases. ► lymphoma Introduction hyperlipasemia may rarely lead to extraabdominal manifes- tations like ectopic subcutaneous fat necrosis and polyarthri- Pancreatic tumors of various histological subtypes can be tis (lipase hypersecretion syndrome).4 encountered in clinical practice, most common being pan- These tumors are hypoenhancing compared with the pan- creatic ductal adenocarcinoma (PDAC), which constitutes creas and are frequently associated with cystic or necrotic 85% of all pancreatic neoplasms.1 Histologically pancreat- areas as well as calcifications5,6 (►Fig.
    [Show full text]
  • Solid Tumour Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Solid Tumour Section Mini Review Lung: Pleuropulmonary blastoma Y Albert Yeh, Morris C Edelman North Shore University Hospital, Long Island Jewish Medical Center, Hofstra University School of Medicine, New York, USA (YAY, MCE) Published in Atlas Database: July 2010 Online updated version : http://AtlasGeneticsOncology.org/Tumors/PleuropulmblastomID6040.html DOI: 10.4267/2042/45006 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology arising in mesenchymal cystic hamartoma, pulmonary Identity blastoma associated with cystic lung disease of Note childhood. Pleuropulmonary blastoma is a rare aggressive malignant tumor of infancy and early childhood. The Clinics and pathology tumor arises in the lung and pleura and is regarded as a pulmonary dysontogenetic or embryonic neoplasm. It is Epidemiology the pulmonary analog of other tumors of childhood There are over 120 cases registered with The including Wilms' tumor, neuroblastoma, Pleuropulmonary Blastoma Registry hepatoblastoma, pancreatoblastoma, and (www.ppbregistry.org). The tumor affects mainly in retinoblastoma. children with age ranges from 1 month to 12 years. Synonyms include embryonal rhabomyosarcoma Most cases are diagnosed before 4 years of age. It can arising in congenital bronchogenic cyst, be found prenatally or present in older children and rhabdomyosarcoma arising in congenital cystic young adults. Males and females are equally affected. adenomatoid malformation, pulmonary sarcoma (A) Type I pleuropulmonary blastoma consists of multiloculated cyst filled with scanty clear serous fluid. (B) The cysts are lined by cuboidal epithelium resting on loose mesenchymal tissue.
    [Show full text]
  • Soft Tissue Sarcoma Classifications
    Soft Tissue Sarcoma Classifications Contents: 1. Introduction 2. Summary of SSCRG’s decisions 3. Issue by issue summary of discussions A: List of codes to be included as Soft Tissue Sarcomas B: Full list of codes discussed with decisions C: Sarcomas of neither bone nor soft tissue D: Classifications by other organisations 1. Introduction We live in an age when it is increasingly important to have ‘key facts’ and ‘headline messages’. The national registry for bone and soft tissue sarcoma want to be able to produce high level factsheets for the general public with statements such as ‘There are 2000 soft tissue sarcomas annually in England’ or ‘Survival for soft tissue sarcomas is (eg) 75%’ It is not possible to write factsheets and data briefings like this, without a shared understanding from the SSCRG about which sarcomas we wish to include in our headline statistics. The registry accepts that soft tissue sarcomas are a very complex and heterogeneous group of cancers which do not easily reduce to headline figures. We will still strive to collect all data from cancer registries about anything that is ‘like a sarcoma’. We will also produce focussed data briefings on sites such as dermatofibrosarcomas and Kaposi’s sarcomas – the aim is not to forget any sites we exclude! The majority of soft tissue sarcomas have proved fairly uncontroversial in discussions with individual members of the SSCRG, but there were 7 particular issues it was necessary to make a group decision on. This paper records the decisions made and the rationale behind these decisions. 2. Summary of SSCRG’s decisions: Include all tumours with morphology codes as listed in Appendix A for any cancer site except C40 and C41 (bone).
    [Show full text]
  • Transcriptional Regulation of IGF-I Receptor Gene Expression by Novel Isoforms of the EWS-WT1 Fusion Protein
    Oncogene (2002) 21, 1890 ± 1898 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein Ina Finkeltov1, Scott Kuhn3,4, Tova Glaser1, Gila Idelman1, John J Wright2, Charles T Roberts Jr3 and Haim Werner*,1 1Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, 69978 Israel; 2Medicine Branch, Division of Clinical Science, National Cancer Institute, NIH, Bethesda, Maryland MD 20889, USA; 3Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon OR 97201, USA The EWS family of genes is involved in numerous Werner et al., 1994a). In addition to its central role in chromosomal translocations that are characteristic of a normal growth processes, the IGF-I-R plays a pivotal variety of sarcomas. A recently described member of this role in malignant transformation (Baserga et al., 1994; group is desmoplastic small round cell tumor (DSRCT), Grimberg and Cohen, 2000; Werner and LeRoith, which is characterized by a recurrent t(11;22)(p13;q12) 1996). The IGF-I-R is highly expressed in most tumors translocation that fuses the 5' exons of the EWS gene to and cancer cell lines, where it functions as a potent the 3' exons of the WT1 gene. The originally described antiapoptotic agent, conferring enhanced survival to chimera comprises exons 1 ± 7 of EWS and exons 8 ± 10 malignant cells (Resnico et al., 1995; Werner and of WT1. We have previously reported that the WT1 LeRoith, 1997). Transcription of the IGF-I-R gene is protein represses the expression of the IGF-I receptor negatively regulated by a number of tumor suppres- gene, whereas the EWS(1 ± 7)-WT1(8 ± 10) fusion protein sors, including p53, BRCA1 and WT1 (Maor et al., activates IGF-I receptor gene expression.
    [Show full text]
  • About Soft Tissue Sarcoma Overview and Types
    cancer.org | 1.800.227.2345 About Soft Tissue Sarcoma Overview and Types If you've been diagnosed with soft tissue sarcoma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is a Soft Tissue Sarcoma? Research and Statistics See the latest estimates for new cases of soft tissue sarcoma and deaths in the US and what research is currently being done. ● Key Statistics for Soft Tissue Sarcomas ● What's New in Soft Tissue Sarcoma Research? What Is a Soft Tissue Sarcoma? Cancer starts when cells start to grow out of control. Cells in nearly any part of the body can become cancer and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 There are many types of soft tissue tumors, and not all of them are cancerous. Many benign tumors are found in soft tissues. The word benign means they're not cancer. These tumors can't spread to other parts of the body. Some soft tissue tumors behave 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 in ways between a cancer and a non-cancer. These are called intermediate soft tissue tumors. When the word sarcoma is part of the name of a disease, it means the tumor is malignant (cancer).A sarcoma is a type of cancer that starts in tissues like bone or muscle. Bone and soft tissue sarcomas are the main types of sarcoma. Soft tissue sarcomas can develop in soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.
    [Show full text]
  • The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
    Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events
    [Show full text]
  • Stage I Clear Cell Sarcoma of the Kidney: Is It the Time for a Less Intensive Adjuvant Treatment?
    Editorial Stage I clear cell sarcoma of the kidney: is it the time for a less intensive adjuvant treatment? Filippo Spreafico1, Lorenza Gandola2, Fraia Melchionda3 1Pediatric Oncology Unit, Hematology and Pediatric Onco-Hematology Department, 2Pediatric Radiotherapy Unit, Department of Radiology/ Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 3Pediatric Oncology and Hematology Unit “Lalla Seràgnoli”, Departement of Pediatrics, University of Bologna, Sant’Orsola-Malpighi Hospital, Bologna, Italy Correspondence to: Filippo Spreafico, MD. Fondazione IRCCS Istituto Naizonale dei Tumori, Milano, Italy. Email: [email protected]. Abstract: Clear cell sarcoma of the kidney (CCSK) is a rare type of renal tumor, comprising 2% to 5% of all primary renal tumors in children. Despite the label of “unfavorable” tumor, with recent multimodality treatment schedules, including radiotherapy and multi-agent chemotherapy, disease free survival rates approaching 80% can be achieved. Younger age at tumor diagnosis and advanced-stage disease represent adverse prognostic factors. Of note, as a consequence of oncologic therapies a number of surviving patients have suffered from late sequelae on the musculoskeletal, gastrointestinal, hepatic, endocrine and cardiovascular function, or developed second tumors. Improved survival rates and a deeper knowledge of iatrogenic complications have promoted the awareness of a sequential reduction of treatment intensity, at least for low-stage CCSK, above all focusing on the abolition of flank radiation therapy (RT). It is fundamental to recognize that the rarity of this tumor calls for international cooperation trough controlled clinical trials, and without forgetting the key importance of a correct histological diagnosis and adequate surgical staging. The recent recognition of CCSK specific chromosomal translocation might help to guide targeted therapies complementary to conventional chemotherapy and radiotherapy.
    [Show full text]
  • Input Data Dictionary Statistics Canada Health Statistics Division
    Component of Statistics Canada Catalogue no. 82-225-XIE2005000 ISSN: 1715-2100 O Canadian Cancer Registry Manual 2005 Input Data Dictionary Statistics Canada Health Statistics Division Canadian Cancer Registry Input Data Dictionary Published by authority of the Minister responsible for Statistics Canada © Minister of Industry, 2003 Material appearing in this publication may be reproduced or copied without permission; however, the following citation to indicate the source must be used: "Data sources: Statistics Canada, Canadian Cancer Registry, Ottawa, 2003." February 2005 Catalogue no. 84-601-XIE Frequency: Irregular Ottawa La version française de cette publication est disponible gratuitement sur le site Internet de Statistique Canada (no 84-601-XIF au catalogue). Note of Appreciation Canada owes the success of its statistical system to a long-standing partnership between Statistics Canada, the citizens of Canada, its businesses, governments and other institutions. Accurate and timely statistical information could not be produced without their continued cooperation and goodwill. Canadian Cancer Registry – Input Data Dictionary Table of Contents Page 1.0 Introduction........................................................................................................................1 1.1 Content of Input Data Dictionary ............................................................................1 1.2 CCR Overview.........................................................................................................2 1.2.1 Canadian Cancer
    [Show full text]
  • Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Clear Cell Sarcoma Models
    1751 Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models Shuzhen Liu, Hongwei Cheng, Wanda Kwan, inhibitors increased expression of SOX9, MYOD1, and Joanna M. Lubieniecka, and Torsten O. Nielsen PPARG and decreased EWS-ATF1 expression in clear cell sarcoma cells. Histone deacetylase inhibitors show prom- Genetic Pathology Evaluation Centre, University of British ising preclinical activity in multiple clear cell sarcoma Columbia, Vancouver, British Columbia, Canada models. [Mol Cancer Ther 2008;7(6):1751–61] Abstract Introduction Clear cell sarcoma is an aggressive malignancy occurring Clear cell sarcoma typically presents in the distal extrem- most commonly in the distal extremities of young adults, ities of young adult patients and is characterized by characterized by t(12;22)(q13;q12) creating the chimeric t(12;22)(q13;q12) (ref. 1). This translocation fuses the 5¶ fusion oncoprotein EWS-ATF1. We assessed growth portion of the Ewing sarcoma (EWSR1) oncogene on inhibition and differentiation effects of histone deacety- chromosome 22q with the 3¶ portion of the activating lase inhibitors MS-275 and romidepsin (depsipeptide, transcription factor 1 (ATF1) oncogene on chromosome FK228) on clear cell sarcoma cells and evaluated drug 12q, resulting in the EWS-ATF1 chimeric fusion oncopro- sensitivity among related translocation-associated sarco- tein. Treatment for clear cell sarcoma is wide excision of mas and other cell models. Three clear cell sarcoma cell the tumor as soon as the diagnosis is established, with lines, seven other sarcomas, six nonsarcoma malignant neoadjuvant or adjuvant radiation therapy to improve the cell lines, and two nonneoplastic mesenchymal cell rate of local control.
    [Show full text]
  • Download Download
    Doi: 10.32677/IJCH.2016.v03.i04.021 Case Report Pain abdomen in a child - An uncommon cause Varun Alwadhi, Aashima Dabas, Anju Aggarwal, M M A Faridi From Department of Pediatrics, University College of Medical Sciences and Guru Tegh Bahadur Hospital, New Delhi, India Correspondence to: Dr. Anju Aggarwal, Flat No. 3C Block, C2B Janakpuri, New Delhi - 110 058, India. Phone: +91-9910329791. E-mail: [email protected] Received – 16 August 2016 Initial Review – 18 September 2016 Published Online – 24 September 2016 ABSTRACT Diagnosis, identification of underlying etiology and management of pain abdomen, remains difficult. Tumors presenting as abdominal pain are rare in children. We report a case of 11-year old boy presenting with pain abdomen. On examination, he had a lump in left hypochondrium. Gastrointestinal tumors constitute about 12% of abdominal masses, 2% of which are pancreatic tumors. He underwent laparotomy was diagnosed as desmoplastic small round cell tumor in the pancreas. This report presents an uncommon cause of a common pediatric problem. Key words: Desmoplastic small round cell tumor, Diagnosis, Outcomes, Pancreas bdominal pain is a common problem in pediatric (Fig. 1). Contrast-enhanced computed tomography of thorax did practice. Common causes of abdominal pain include not reveal any metastasis. Bone marrow aspiration was normal. The Aenteritis, infection, worm infestation, constipation, patient underwent open laparotomy with resection of pancreatic food allergy, peptic ulcer, and obstruction. Tumors presenting body and tail and splenectomy and removal of adjoining lymph as abdominal pain are rare in children. Most common tumor nodes (Fig. 2). Post-operative histopathology findings confirmed masses in childhood are neuroblastoma, Wilm’s tumors, non- the diagnosis of DSRCT of the pancreas (Grade 4-undifferentiated, Hodgkin’s lymphoma, germ cell tumor, and hepatoblastoma [1].
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]